Edit
Forma Therapeutics
https://www.formatherapeutics.com/Last activity: 02.09.2022
Probably Closed - Reference to Novo Nordisk
Forma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.
We aim to create futures for patients, their families and our employees.
Learn more about our mission, discover our “Whole You” benefits package and search for your next career opportunity: https://www.formatherapeutics.com/careers/
Read our community guidelines: https://www.formatherapeutics.com/community-guidelines/
We aim to create futures for patients, their families and our employees.
Learn more about our mission, discover our “Whole You” benefits package and search for your next career opportunity: https://www.formatherapeutics.com/careers/
Read our community guidelines: https://www.formatherapeutics.com/community-guidelines/
Location: Canada, Saskatchewan, Watertown
Employees: 51-200
Total raised: $100M
Founded date: 2007
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Koa Labs | koalab.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.12.2019 | Series D | $100M | - |
Mentions in press and media 16
| Date | Title | Description |
| 02.09.2022 | Novo Nordisk to buy sickle cell disease biotech Forma Therapeutics in $1.1B deal | Novo Nordisk announced a big purchase on Thursday to augment its rare disease portfolio. The Danish pharmaceutical giant is shelling out $20 per share in cash to acquire clinical-stage biotech Forma Therapeutics, which focuses on rare hemat... |
| 13.12.2021 | Forma Therapeutics' : Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease - Form 8-K | Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Se... |
| 13.12.2021 | FORMA THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Other Events (form 8-K) | Item 7.01. Regulation FD Disclosure. On December 11, 2021, Forma Therapeutics Holdings, Inc. (the Company) issued a press release titled "Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red B... |
| 09.12.2021 | Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease | Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD), prostate cancer and other rare hematologic diseases and cancers, today announced formabridge. Through formabr... |
| 19.12.2019 | Forma Therapeutics nets $100M to push sickle cell treatment | Genentech veteran Frank Lee landed at Forma Therapeutics as it aimed to transition from an early discovery and development company to one that was knocking on the door of approvals and commercialization. Now, Forma is reeling in $100 millio... |
| 19.12.2019 | Forma Therapeutics Closes $100M Series D Financing | Forma Therapeutics, Inc., a Watertown, Mass. – based clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, closed a $100m Series D financing. The round was led by RA Capital Management, with participatio... |
| 19.12.2019 | FORMA Therapeutics Announces Closing of $100 Million Series D Financing | WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of $100 million Series D financing. The financing was led ... |
| 19.12.2019 | Forma Therapeutics nets $100M to push sickle cell treatment | Genentech veteran Frank Lee landed at Forma Therapeutics as it aimed to transition from an early discovery and development company to one that was knocking on the door of approvals and commercialization. Now, Forma is reeling in $100 millio... |
| 19.12.2019 | Forma Therapeutics Raises $100M Series D | WATERTOWN, MA, FORMA Therapeutics today announced the closing of $100 million Series D financing. >> Click here for more funding data on Forma Therapeutics >> To export Forma Therapeutics funding data to PDF and Excel, click... |
| 31.08.2016 | Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D into a separate company | Takeda is rolling out a major new study involving multiple myeloma patients. Researchers are recruiting 5,000 patients to track their real world experience in being treated for the disease. Takeda bagged an FDA approval... |
Show more